TECLISTAMAB-CQYV

Other

Brand names: TECVAYLI

Subcutaneous

Mechanism of Action

12.1 Mechanism of Action Teclistamab-cqyv is a bispecific T-cell engaging antibody that binds to the CD3 receptor expressed on the surface of T-cells and B-cell maturation antigen (BCMA) expressed on the surface of multiple myeloma cells and some healthy B-lineage cells. In vitro , teclistamab-cqyv activated T-cells, caused the release of various proinflammatory cytokines, and resulted in the lysis of multiple myeloma cells.

Indications

including a proteasome inhibitor and an immunomodulatory agent. as monotherapy

in patients who have received at least four prior lines of therapy

including a proteasome inhibitor

including a proteasome inhibitor and an immunomodulatory agent ( 1 ). as monotherapy

in patients who have received at least four prior lines of therapy

including a proteasome inhibitor

Contraindications

• 4 CONTRAINDICATIONS None. None. ( 4 )

FDA Warnings

5 WARNINGS AND PRECAUTIONS Hepatotoxicity : Can cause hepatotoxicity, including fatalities
4 ) Infections : Can cause severe, life-threatening, or fatal infections
Advise females of reproductive potential of the potential risk to the fetus and to use effective contraception
1 Cytokine Release Syndrome TECVAYLI can cause cytokine release syndrome (CRS), including life-threatening or fatal reactions [see Adverse Reactions (6

Known Side Effects

0 documented side effects by frequency

No structured side effect data available.

Community Discussions

No community discussions found for TECLISTAMAB-CQYV yet.

Compare With

0 available comparisons

No comparisons yet.

Formulations

Dosage Forms

Tablet

Route

Subcutaneous